Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04982328 Completed - Covid19 Clinical Trials

COVID-19 and Nonalcoholic Fatty Liver Disease

CovidFAT
Start date: April 1, 2021
Phase:
Study type: Observational

COVID-19 is currently the leading public health problem, associated with a high risk of complications and death in risk groups of patients. Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease with a prevalence of 30% in the Western population and is also recognized as an independent risk factor for the development of severe COVID-19. In the pathogenesis of COVID-19, the key role is played by the hyperreactivity of the immune response, the so-called cytokine storm leading to the development of severe forms of pneumonia, acute respiratory and multiorgan failure. The aim of this study is to investigate the clinical course, outcomes, and profile of inflammatory response in patients with COVID-19 and NAFLD.

NCT ID: NCT04982263 Completed - Covid19 Clinical Trials

Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients

Start date: February 1, 2021
Phase:
Study type: Observational

The role of the coagulation parameters in predicting the severity of COVID-19 disease will be assessed

NCT ID: NCT04982068 Active, not recruiting - COVID-19 Clinical Trials

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Start date: July 12, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and preliminary immunogenicity of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and above.

NCT ID: NCT04982042 Recruiting - Covid19 Clinical Trials

Post COVID-19 Pulmonary Rehabilitation Program

COVID19REHAB
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Coronavirus-2019 disease (COVID-19) is a highly infectious respiratory disease that causes respiratory, physical and psychological dysfunction in patients. With the increased understanding of the severity of COVID-19 and clinical evidence in accordance with the opinions of first-line clinical experts involved in the treatment of this epidemic, the investigators believe that the participation of patients with sequelae of COVID-19 in a Pulmonary Rehabilitation Program would be of utmost importance. According to recent scientific recommendations for patients with sequelae of COVID-19, respiratory rehabilitation would alleviate symptoms of dyspnea, anxiety and depression and, eventually, improve physical functions and quality of life. Therefore, it is essential to anticipate early rehabilitation after the acute phase of ARDS, in order to limit the severity of the effects of the ICU and promote rapid functional recovery. Physiotherapy will play a role in providing exercise, mobilization and rehabilitation interventions for survivors of critical illnesses associated with COVID-19, in order to enable a functional social return.

NCT ID: NCT04981769 Not yet recruiting - Covid19 Clinical Trials

POC SARS-CoV-2 Diagnostic PCR Device Comparison to FDA Approved Reference PCR Test

Start date: August 2, 2021
Phase:
Study type: Observational

Study will assess sensitivity and specificity of AnavasiDx POC PCR device for detection of Covid-19 in patients presenting for testing a clinical sites.

NCT ID: NCT04981743 Recruiting - Covid19 Clinical Trials

The Efficacy of Nigella Sativa Versus VitaminD3 as Supplement Therapy in Coronavirus Disease 2019 (COVID-19)

COVID-19
Start date: July 21, 2021
Phase: N/A
Study type: Interventional

The aim this study is to investigate the safety and efficacy of Nigella Sativa versus Vitamin D3 versus Nigella Sativa / vitamin D3 combination as supplement for management of COVID-19 .

NCT ID: NCT04981535 Completed - Covid19 Clinical Trials

Aerosol Particle From EGD in Patients With and Without Head Box in COVID-19 Era

Start date: September 30, 2021
Phase: N/A
Study type: Interventional

According to preexisting data, it has revealed the fundamental role that aerosols play in the transmission of the COVID-19 virus. Esophagogastroduodenoscopy (EGD), producing particle smaller than 5 microns, was regarded as 'aerosol-generating procedures' (AGPs) associated with an increased risk of transmission of respiratory pathogens to healthcare workers. The strategies aim to reduce spreading of aerosol during the procedure should be beneficial. Using an acrylic box to cover the head of a patient undergoing an endoscopy seems to reduce aerosol scatter and reduce the spread of respiratory pathogens. At present, there are no high-quality studies that provide quantitative data on the use of head box to reduce aerosol generation.

NCT ID: NCT04981405 Terminated - COVID-19 Pneumonia Clinical Trials

Real-world Evidence of COVID-19 Vaccines Effectiveness

Start date: July 16, 2021
Phase:
Study type: Observational

This is an observational case-control study to evaluate COVID-19 vaccine effectiveness against hospitalisation with COVID-19 related conditions in St. Petersburg, Russia. Two sets of cases and control will be retrospectively analyzed to compare vaccination proportions and other characteristics to infer vaccine effectiveness from odds ratios. The first set of cases will be extracted from the data on hospitalisation of patients with COVID-19 to First Pavlov State Medical University of Saint-Petersburg hospitals, and controls will be patients hospitalised with other conditions. The second set of cases and controls will be based on patients referred to Medical Institute named after Berezin Sergey for computed tomography. Cases will be patients with positive SARS-CoV-2 status computed tomography confirmed pneumonia or patients referred to hospitalisation, and control will be patients without pneumonia and not referred to hospitalisation.

NCT ID: NCT04981392 Completed - Covid19 Clinical Trials

Intervention to Promote COVID-19 Vaccination

Start date: June 2, 2022
Phase: N/A
Study type: Interventional

The study aims to implement and assess the impact of a multi-faceted intervention to support Primary Care Provider (PCP) outreach, and PCP and community organization dissemination of information to promote COVID-19 vaccination among vulnerable patients in and near Worcester, MA.

NCT ID: NCT04981379 Completed - Covid19 Clinical Trials

Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment

Start date: November 16, 2020
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blinded, and placebo controlled phase III clinical trial which aims to investigate the superiority of hydroxychloroquine, favipiravir or hydroxychloroquine + favipiravir treatment, initiated especially in the early period in the treatment of COVID-19, over the patients being followed up with placebo in adults aged 18~59 Years.